Pernix Pharma

Pernix Therapeutics was a specialty pharmaceutical company focused on the acquisition, development, and commercialization of prescription drugs for underserved therapeutic areas. The company primarily targeted central nervous system (CNS) disorders, with a portfolio featuring treatments for insomnia, migraine, and chronic pain management. Key commercial products included Silenor for sleep maintenance, Treximet for acute migraine, and Zohydro ER for severe chronic pain. Following financial challenges, the company filed for Chapter 11 bankruptcy in early 2019. Its assets and operations were subsequently acquired by Currax Pharmaceuticals, which continues to manage the legacy Pernix portfolio.